Abemaciclib

About

Therapy type: Targeted therapy

Therapy strategy: CDK4/6 inhibition

Mappings

NCI Thesaurus: Abemaciclib (ncit:C97660)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Tamoxifen
EMA (1) FDA (1) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
EMA (2) FDA (2) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Anastrozole
EMA (2) FDA (2) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
EMA (2) FDA (2) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
EMA (2) FDA (2) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Letrozole
EMA (2) FDA (2) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
EMA (2) FDA (2) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
EMA (1) FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Fulvestrant
EMA (1) FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant
EMA (1) FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant
FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib
FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Exemestane
EMA (1) FDA (1) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane